$51.36-0.7%Nov 13 close
Figures through September 30, 2026, from the 6-K filed November 5, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.2B | $925M | +28.32% |
| Profit | $342M | $336M | +1.79% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Genmab A/S reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The third quarter of 2026 reinforced the breadth of our late-stage portfolio. TEPKINLY plus R 2 became the first bispecific-based therapy approved in Europe for second-line FL, extending epcoritamab's reach as a core therapy across B-cell malignancies. We also broadened our petosemtamab program with new Phase 3 studies in CRC, underscoring our confidence in this asset beyond head and neck cancer. As anticipated, we are now in our data-rich fourth quarter, where we have delivered pivotal readouts across our three late-stage assets, epcoritamab, Rina-S ® (rinatabart sesutecan) and petosemtamab, supporting multiple regulatory submissions and potential launches in 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
The quote and the company description come from the 6-K Genmab A/S filed on November 5, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.